Treatment of multiple myeloma patients with the CD38 antibody Daratumumab: focus on in vivo effector mechanisms

Jakub Krejcik

Publikation: AfhandlingPh.d.-afhandling

OriginalsprogEngelsk
Udgiver
StatusUdgivet - 2017

Citationsformater